Patient health and well-being depends on the uninterrupted availability of lower-cost generic and biosimilar medicines. Moreover, as patients live longer the importance of a robust and sustainable generic and biosimilar medicines industry becomes only that much more important. Policymakers must act quickly to ensure continued saving and market-based competition, as well as prevent shortages, for future availability of affordable medicines. This requires:
AAM All Access Podcast - Dan Leonard speaks to David Gaugh (AAM), Jessica Daley (Premier Inc) and Steven Schondelmeyer (University of Minnesota).